Pharma Sector

From March 28 to April 4, 2024, the US drug regulator conducted a normal current Good Manufacturing Practices (cGMP) inspection at the site.

The block deal has a floor price of ₹331 per share, which is 7.1% lower than Thursday's closing price, according to sources.

Cipla stated in an exchange statement that this extra investment, made through a convertible loan, will accelerate the company's engagement in the mRNA space.

Although the firm has not detailed the nature of the observations, it has stated that JHSGP would submit an action plan based on the observations.

Fosun Pharma, a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co, owns approximately 58% of Gland Pharma, with a market value of $3.6 billion.

According to Zydus Lifesciences, the categorization follows an inspection conducted by the USFDA from March 18 to 27, 2024.

The oligonucleotide building blocks market is valued at $750 million and is predicted to develop at a 20% CAGR.

According to the company, the parties will sign a commercial supply agreement under which Ingenus will deliver the product to Dr. Reddy's USA.

Gland Pharma said that its consolidated profit after tax (PAT) increased more than twofold to ₹192 Crore in the March quarter.

The availability of P-CABs such as Kabvie will allow the Indian people to access innovative and effective GERD treatments.